Breast cancer affects more women than any other type of cancer, and represents 15% of all new cancer cases in the United States. A total of 252,710 new breast cancer cases were estimated to be diagnosed in 2017, and more than 40,600 deaths. The prognosis worsens for patients with locally advanced breast cancer and even more so for those with metastatic disease. Read More ›

In patients with HR-positive breast cancer, a positive circulating tumor cells assay result was associated with nearly a 20-fold increased risk for recurrence of disease. Read More ›

Older women with hormone receptor–positive, HER2-negative metastatic breast cancer who are treated with a CDK4/6 inhibitor may derive benefits similar to those seen in their younger counterparts. Read More ›

At 10-year follow-up, investigators observed similar outcomes with exemestane alone and sequential tamoxifen/exemestane in the phase 3 TEAM trial of postmenopausal women with hormone receptor (HR)-positive early breast cancer. Read More ›

The results of a recent gene-sequencing analysis identify new pathogenic mutations associated with an increased risk for breast cancer. Read More ›

The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations. Read More ›

Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer. Read More ›